Murepavadin - Polyphor

Drug Profile

Murepavadin - Polyphor

Alternative Names: POL 7080; POL 7080 acetate; RG 7929; RO 7033877

Latest Information Update: 07 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Polyphor; University of Zurich
  • Developer Polyphor
  • Class Antibacterials; Cyclic peptides
  • Mechanism of Action Imp protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pseudomonal infections
  • No development reported Gram-negative infections

Most Recent Events

  • 10 Jul 2018 Polyphor plans the PRISM-UDR phase III trial for Pseudomonal infections in August 2018 , (NCT03582007)
  • 24 Apr 2018 Antimicrobial data from a preclinical trial in Pseudomonal infections presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2018)
  • 21 Apr 2018 Antimicrobial data from a preclinical trial in Pseudomonal infections presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top